3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
2
Completed
2
Withdrawn
1
Unknown
1
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Observational
2
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Gastrointestinal
1
Conditions
Breast Neoplasms
4997
Neoplasms
4192
Prostatic Neoplasms
2426
Carcinoma, Non-Small-Cell Lung
2261
Colorectal Neoplasms
2050
Lung Neoplasms
1703
Multiple Myeloma
1454
Lymphoma
1403
Leukemia, Myeloid, Acute
1379
Neoplasm Metastasis
1372
Melanoma
1269
Pancreatic Neoplasms
1200
Leukemia
1194
Ovarian Neoplasms
1190
Lymphoma, Non-Hodgkin
1128
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1088
Head and Neck Neoplasms
1055
Leukemia, Lymphocytic, Chronic, B-Cell
994
Lymphoma, Follicular
896
Colonic Neoplasms
893
Brain Neoplasms
875
Stomach Neoplasms
854
Recurrence
848
Carcinoma, Hepatocellular
845
Glioblastoma
837
Lymphoma, Large B-Cell, Diffuse
770
Rectal Neoplasms
758
Uterine Cervical Neoplasms
725
Carcinoma, Renal Cell
704
Hodgkin Disease
696
Interventions
tazemetostat
1
relatlimab
1
durvalumab
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Interventional
×
Tertiary Lymphoid Structures
×
Clear all
NCT04095208
2026-04-21
CONGRATS
Institut Bergonié
Phase 2
Completed
68 enrolled
NCT04705818
2026-03-06
CAIRE
Institut Bergonié
Phase 2
Completed
164 enrolled